LONDON, Nov 30 (Reuters) - Privately owned British biotech company PIramed Ltd said on Wednesday it had signed a deal potentially worth up to $230 million with Genentech Inc. (DNA.N: Quote, Profile, Research) for the development of a new class of cancer drugs.
